NEW YORK, November 15, 2016 /PRNewswire/ --
This morning, Stock-Callers reviews the Dug Makers segment with focus on four equities: Amphastar Pharmaceuticals Inc.
(NASDAQ: AMPH), United Therapeutics Corporation (NASDAQ: UTHR), MEI Pharma Inc. (NASDAQ: MEIP), and SciClone Pharmaceuticals Inc.
(NASDAQ: SCLN). Today's coverage follows Monday's mixed trading session as the NASDAQ Composite and the S&P 500 closed down
for the day, while the Dow Jones Industrial Average managed to finish the session 0.11% higher. You can access of our
complimentary research reports on these stocks now at:
http://stock-callers.com/registration
Amphastar Pharma
On Monday, shares in Rancho Cucamonga, California headquartered Amphastar Pharmaceuticals
Inc. ended the session 1.96% lower at $20.52 with a total volume of 525,426 shares traded.
Amphastar Pharma's shares have surged 14.00% in the last one month, 11.89% in the previous three months, and 47.63% in the past
one year. Shares of the Company, which focuses on the development, manufacture, marketing, and sale of generic and proprietary
injectable, inhalation, and intranasal products, are trading at a PE ratio of 45.50. The stock is trading 8.67% above its 50-day
moving average and 32.13% above its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI)
of 61.82. Visit us today and download your complete report on AMPH for free at:
http://stock-callers.com/registration/?symbol=AMPH
United Therapeutics
Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock finished Monday's
session 5.79% higher at $134.35 with a total volume of 962,094 shares traded. Over the last one
month and the previous three months, United Therapeutics' shares have gained 14.94% and 7.29%, respectively. Shares of the
Company, which develops and commercializes products to address the unmet medical needs of patients with chronic and
life-threatening diseases worldwide, are trading above its 50-day and 200-day moving averages by 11.77% and 14.13%, respectively.
United Therapeutics' stock traded at a PE ratio of 9.06 and has an RSI of 68.94.
On October 28th, 2016, research firm Ladenburg Thalmann upgraded the Company's stock
rating from 'Neutral' to 'Buy'. The complimentary research report on UTHR can be accessed at:
http://stock-callers.com/registration/?symbol=UTHR
MEI Pharma
On Monday, shares in San Diego, California-based MEI Pharma Inc. recorded a trading volume of
188,746 shares. The stock ended the day 2.41% lower at $1.62. The stock is trading above its
200-day moving average by 9.63%. Furthermore, shares of MEI Pharma, which focuses on the clinical development of drugs for the
treatment of cancer, have an RSI of 53.72. Register for free on Stock-Callers.com and download the PDF research report on MEIP
at:
http://stock-callers.com/registration/?symbol=MEIP
SciClone Pharma
Foster City, California headquartered SciClone Pharmaceuticals Inc.'s stock advanced 5.08%,
to close the day at $10.35. The stock recorded a trading volume of 1.66 million shares, which was
above its three months average volume of 394,130 shares. SciClone Pharma's shares have advanced 3.40% in the previous one month
and 12.99% in the past one year. Shares of the Company, which provides therapies for oncology, infectious diseases, and
cardiovascular disorders in the People's Republic of China, the US, and Hong Kong, are trading 4.12% above its 50-day moving average. Additionally, the stock traded at a PE ratio
of 13.91 and has an RSI of 61.90. Get free access to your research report on SCLN at:
http://stock-callers.com/registration/?symbol=SCLN
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA